Search for Actavis and
    1. July 27, 2015

      Allergan signals appetite for new mega deal after $41bn disposal

      It is just over a year since Brent Saunders became chief executive of Allergan, then known as Actavis, but he has...

    2. July 27, 2015

      Pharma M&A: portfolio theory

      Friendly M&A is cheaper and simpler than the hostile variety. Luckily for Teva Pharmaceutical it had a choice. On...

    1. July 6, 2015

      Teva set to lift Mylan bid to up to $43bn

      Teva, the Israeli drugmaker, is preparing to increase its offer for US rival Mylan to as much as $43bn as soon as this...

    2. June 21, 2015

      Allergan aims to keep beauty lead as needle replaces the knife

      As any Beverly Hills “mom” will tell you, facelifts are old news. The rise of injectable wrinkle smoothers such as...

    3. June 17, 2015

      Frozen forehead meets double chin

      Allergan, the owner of Botox, said on Wednesday it would spend $2.1bn on a biotech group that makes a treatment...

    4. June 3, 2015

      The riff: Bruno Lafont’s early bonus

      There are many examples of bosses who get paid extra just for doing their job. But the recent rash of “golden...

    5. May 17, 2015

      The Botox initiation of Brent Saunders, Actavis chief executive

      “I was a little ambushed,” says Brent Saunders, recalling how he ended up having his face injected with Botox and other...

    6. May 10, 2015

      Greek Eurogroup talks dominate week ahead agenda

      A UK general election that delivered an unexpectedly decisive outcome sent the pound soaring this week, but investors...

    7. April 10, 2015

      Fredric Brandt, cosmetic dermatologist, 1949-2015

      Dermatologist to the stars, Fredric Brandt had a client list that included Madonna, not to mention a string of others...

    8. March 29, 2015

      Monday interview: Thor Bjorgolfsson, investor

      Thor Bjorgolfsson, biker, self-confessed deal addict, “adventure capitalist” and once Iceland’s most bank­able...

    9. March 26, 2015

      Omega Advisors probed over share trading

      Leon Cooperman, founder of the $12.7bn hedge fund Omega Advisors, has defended his stock research practices, after...

    10. March 26, 2015

      Actavis rewrites ‘big pharma’ playbook

      Move over GlaxoSmithKline. There is a new pharmaceuticals giant in town. After completing its $70bn acquisition of...

    11. March 5, 2015

      AbbVie joins the pharma chain reaction

      As executives from Johnson & Johnson huddled with their advisers, including Goldman Sachs, late on Wednesday, there was...

    12. March 3, 2015

      Actavis’s $21bn bond sale is second-largest on record

      Actavis sold $21bn of bonds on Tuesday in the second-largest corporate debt offering on record, to help fund its $66bn...

    13. February 11, 2015

      M&A helps lift US healthcare stocks

      Gilead Sciences, the biotech behemoth that has seen its market valuation soar to a cool $145bn, has put in a strong...

    14. February 10, 2015

      Healthcare: The race to cure rising drug costs

      Since contracting hepatitis C 25 years ago, Lucinda Porter’s biggest fear has been that she would infect someone else...

    15. February 5, 2015

      AstraZeneca to pay $600m for Actavis respiratory drugs

      AstraZeneca has agreed to pay $600m for the rights to Actavis’s branded respiratory drugs business in North America as...

    16. January 21, 2015

      Hungry Actavis pauses to digest Allergan

      When David Pyott, chief executive of Allergan, hands out his business card, he describes it as “a collector’s item that...

    17. January 21, 2015

      Actavis and Valeant raise prospect of more pharma deals

      Two of the most acquisitive pharmaceuticals groups have pledged to continue pursuing deals in 2015, raising the...

    18. January 4, 2015

      Allergan takeover saga ended with deal of the year

      For the past three decades the great and the good of the pharmaceuticals industry have descended on San Francisco for a...

    19. November 21, 2014

      Allergan deal sits well on Actavis chief’s ‘Monopoly board’

      When Paul Bisaro, executive chairman of Actavis, raised the idea of buying Allergan this summer, he prompted some...

    20. November 18, 2014

      Actavis’ dealmaking builds drug powerhouse

      Just two years ago Actavis, then known as Watson Pharmaceuticals, was a run-of-the-mill maker of generic drugs with a...

    21. November 17, 2014

      Allergan sees off Valeant by sealing $66bn deal with Actavis

      Actavis-Allergan deal Allergan ended the year’s ugliest and longest-running takeover battle on Monday after the Botox...

    22. November 17, 2014

      Allergan-Actavis deal follows battle for soul of pharma

      Actavis-Allergan deal The sale of Allergan to Actavis for about $66bn is set to be the biggest takeover in a frantic...

    23. November 16, 2014

      Actavis to pay $66bn for Allergan

      Allergan, the maker of Botox, has agreed to sell itself in a $66bn deal with fellow drugs group Actavis , with rival...

    24. November 7, 2014

      Pharma wars: upset stomach

      It’s not a good sign when a bowel medicine company feels bloated. Salix Pharmaceuticals, a drug company focused on...

    25. November 6, 2014

      Perrigo joins wave of OTC drug deals

      Perrigo said it had joined the big league of global over-the-counter drugmakers after agreeing a €3.6bn acquisition of...

    26. October 16, 2014

      Tax changes roil inversion deals

      The sudden collapse of AbbVie’s proposed $54bn takeover of rival drugmaker Shire does not necessarily signal that the...

    27. October 9, 2014

      Takeover target Allergan raises guidance

      Allergan, the maker of blockbuster wrinkle treatment Botox, has boosted its earnings forecast for the third quarter and...

    28. October 8, 2014

      Valeant and Pershing look to sweeten Allergan bid by $4.5bn

      Valeant Pharmaceuticals and Bill Ackman’s Pershing Square are considering sweetening their offer for Allergan by...

    29. October 3, 2014

      Salix pulls deal amid US tax crackdown

      A $2.7bn deal between drugmakers Salix of the US and Cosmo of Italy has become the first victim of President Barack...

    30. September 28, 2014

      Drugs groups trapped in tangled M&A web

      When Valeant offered almost $46bn to buy Allergan in April, it seemed like a large but relatively straightforward deal....

    31. July 14, 2014

      Mylan in $5.3bn Abbott Laboratories deal

      US pharmaceuticals group Mylan has agreed to pay $5.3bn for the generic drugs business of Abbott Laboratories, in...

    32. February 26, 2014

      Hedge funds should not be the only activist investors

      At 78, Carl Icahn shows little sign of retiring, or of becoming more polite. After finally prodding Forest Labs into a...

    33. February 21, 2014

      Carl Icahn, obsessive activist investor

      Steven Goldstone, when he was chief executive of RJR Nabisco, used to call the appearance of Carl Icahn “a rite of...

    34. February 21, 2014

      Letter from Lex: the end of investing

      If a company that has designed a single successful mobile phone game can be worth $5bn, anything can be worth anything,...

    35. February 19, 2014

      Eli Lilly jumps after cancer drug trial

      Shares in Eli Lilly climbed after the US pharmaceuticals group said a study of a lung cancer treatment increased...

    36. FT Alphaville

      February 18, 2014

      The Closer

      FURTHER FURTHER READING - Kevin Roose crashes a Wall Street secret society. - Minimum wage by the numbers. - Arnold...

    37. February 18, 2014

      Actavis chief Bisaro finds prescription for growth

      Paul Bisaro, the outspoken chief executive of drugs company Actavis, has quickly gained a reputation as an ambitious...

    38. February 18, 2014

      Actavis / Forest: roll up, tax down

      Buy drug company, cut operating costs, cut research spending, pay less tax, watch stock go up. It is a simple plan, and...

    Search for Actavis and